Related Experiment Video
Updated: May 26, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Risk factors associated with relapse in Japanese patients with microscopic polyangiitis
Takashi Wada1, Akinori Hara, Yoshihiro Arimura
1Division of Nephrology, Department of Laboratory Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. twada@m-kanazawa.jp
Objective:
We retrospectively studied the risk factors associated with relapse during remission maintenance therapy for myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA).
Methods:
Sixty-two patients diagnosed with MPA according to the European Medicines Agency classification algorithm during a 2-year period from January 1, 2005, to December 31, 2006, and who achieved remission after the first remission-induction therapy, were examined (registration no. UMIN000001785).
Results:
The patient group comprised 25 men and 37 women aged 70.0 ± 8.9 years. The mean observation period was 30.2 ± 15.9 months. The rate of relapse was 24.2% (15/62), and mean interval between remission and relapse was 16.9 ± 13.5 months. During maintenance therapy following remission, the risk of relapse increased when the reduction rate of prednisolone increased above 0.8 mg/month (OR 12.6, 95% CI 2.2-97.9). Proteinuria at the start of maintenance therapy (regression coefficient 1.991 ± 0.758, p < 0.05) and the change in red blood cell counts in urine during the period from the start of maintenance therapy to the final observation (regression coefficient 0.126 ± 0.040, p < 0.01) were identified as risk factors influencing the vasculitis damage index.
Conclusion:
In Japan, relapse of MPO-ANCA-positive MPA may be associated with the reduction rate of oral prednisolone administration during maintenance therapy.
Insights
Relapse in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive microscopic polyangiitis (MPA) is linked to how quickly prednisolone is reduced during maintenance therapy. Careful monitoring of prednisolone reduction rates is crucial for preventing MPO-ANCA-positive MPA relapses.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Microscopic polyangiitis (MPA) is a serious autoimmune condition.
- Myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA) positivity is a key diagnostic marker for MPA.
- Maintaining remission in MPA is critical to prevent disease flares and organ damage.
Purpose of the Study:
- To identify risk factors for relapse during maintenance therapy in MPO-ANCA-positive MPA patients.
- To investigate the association between prednisolone reduction rates and relapse risk.
- To understand predictors of vasculitis damage index in MPA.
Main Methods:
- Retrospective study of 62 MPA patients achieving remission.
- Analysis of patient data from January 2005 to December 2006.
- Statistical analysis to identify risk factors for relapse and vasculitis damage index.
Main Results:
- Relapse rate was 24.2% (15/62) with a mean remission-relapse interval of 16.9 months.
- Increased risk of relapse observed when prednisolone reduction rate exceeded 0.8 mg/month (OR 12.6).
- Proteinuria and changes in urinary red blood cell counts were risk factors for vasculitis damage index.
Conclusions:
- The rate of prednisolone reduction during maintenance therapy is a significant factor associated with relapse in MPO-ANCA-positive MPA in Japan.
- Close monitoring of prednisolone tapering is essential for managing MPO-ANCA-positive MPA.
- Proteinuria and hematuria changes may indicate increased disease activity or damage.
Related Concept Videos
Drug Toxicity: Risk factors
Psychological and Sociocultural Causes of Schizophrenia
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Nephrotic Syndrome II : Assessment and Medical Management
Inflammatory Bowel Disease III: Crohn's Disease
Nephrotic Syndrome I : Introduction
